28 July 2016
Succesful safety evaluation of PAMVAC vaccine
ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical trial of the placental malaria vaccine candidate, PAMVAC.
Due to the trial’s staggered approach, the second evaluation allows initiation of the phase Ib clinical trial to be conducted in Benin, Africa.
The clinical trial is funded by the EU under the FP7 program and coordinated by associate professor Morten A Nielsen at University of Copenhagen in collaboration with University of Tübingen, Université d’Abomey-Calavi, European Vaccine Initiative, Institut de Recherche pour le Développement, and ExpreS2ion Biotech.
Read the full Press Release here.